Single dose of ivermectin inhibits COVID-19


  • Heather Mason
  • Univadis Medical News
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

An Australian research group has shown that the anti-parasitic drug ivermectin inhibits integrase protein import of COVID-19, according to a report published in Antiviral Research

Ivermectin has previously been  identified as an inhibitor of interaction between HIV-1 integrase protein (IN) and the importin (IMP) α/β1 heterodimer responsible for IN nuclear import.

In vitro cells were infected with COVID-19 isolate Australia/VIC01/2020 for two hours, followed by the addition of 5αM of ivermectin. At 24 hours, a 93% reduction in viral RNA was present in the supernatant of samples treated with Ivermectin that controls.

Similarly, a 99.8 per cent reduction in cell-associated viral RNA was seen at 48 hours, indicating unreleased and unpackaged virions. No further viral replication was observed at 72 hours.

The half-maximal inhibitory concentration (IC50) of ivermectin treatment was determined to be approximately 2αM under the same conditions. Reverse transcription-polymerase chain reaction (RT-PCR) using primers for the viral RdRp gene reproduced the results almost identically.

Ivermectin has an established safety profile for human use. This report raises the possibility that ivermectin could be a useful antiviral to limit COVID-19. A critical next step will be to evaluate dosing regimens.